These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 36497061)

  • 21. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
    Harold J; Bellone S; Manavella DD; Mutlu L; McNamara B; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MS; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2023 Jan; 168():157-165. PubMed ID: 36442427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.
    Brewer Savannah KJ; Demicco EG; Lusby K; Ghadimi MP; Belousov R; Young E; Zhang Y; Huang KL; Lazar AJ; Hunt KK; Pollock RE; Creighton CJ; Anderson ML; Lev D
    Clin Cancer Res; 2012 Sep; 18(17):4633-45. PubMed ID: 22821997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
    McNamara B; Harold J; Manavella D; Bellone S; Mutlu L; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Yang K; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Burton EA; Inagaki H; Albers A; Zhang C; Bollag G; Schlessinger J; Santin AD
    Gynecol Oncol; 2023 May; 172():65-71. PubMed ID: 36958197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of miR‑10b‑5p facilitates the proliferation of uterine leiomyosarcoma cells: A microRNA sequencing‑based approach.
    Yoshida K; Yokoi A; Kitagawa M; Sugiyama M; Yamamoto T; Nakayama J; Yoshida H; Kato T; Kajiyama H; Yamamoto Y
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 36929268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.
    Dhingra S; Rodriguez ME; Shen Q; Duan X; Stanton ML; Chen L; Zhang R; Brown RE
    Int J Clin Exp Pathol; 2010 Jan; 4(2):134-46. PubMed ID: 21326806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting homologous recombination deficiency in uterine leiomyosarcoma.
    Dall G; Vandenberg CJ; Nesic K; Ratnayake G; Zhu W; Vissers JHA; Bedő J; Penington J; Wakefield MJ; Kee D; Carmagnac A; Lim R; Shield-Artin K; Milesi B; Lobley A; Kyran EL; O'Grady E; Tram J; Zhou W; Nugawela D; Stewart KP; Caldwell R; Papadopoulos L; Ng AP; Dobrovic A; Fox SB; McNally O; Power JD; Meniawy T; Tan TH; Collins IM; Klein O; Barnett S; Olesen I; Hamilton A; Hofmann O; Grimmond S; Papenfuss AT; Scott CL; Barker HE
    J Exp Clin Cancer Res; 2023 May; 42(1):112. PubMed ID: 37143137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The inhibitory effects of class I histone deacetylases on hippocampal neuroinflammatory regulation in aging mice with postoperative cognitive dysfunction.
    Yang CX; Bao F; Zhong J; Zhang L; Deng LB; Sha Q; Jiang H
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):10194-10202. PubMed ID: 33090427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGFR4 promotes nuclear localization of GABP to inhibit cell apoptosis in uterine leiomyosarcoma.
    Zhang P; Zhang H; Wang Y
    Cell Tissue Res; 2021 Feb; 383(2):865-879. PubMed ID: 33151453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylases: unique players in shaping the epigenetic histone code.
    Thiagalingam S; Cheng KH; Lee HJ; Mineva N; Thiagalingam A; Ponte JF
    Ann N Y Acad Sci; 2003 Mar; 983():84-100. PubMed ID: 12724214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
    Korfei M; Mahavadi P; Guenther A
    Cells; 2022 May; 11(10):. PubMed ID: 35626663
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Seligson ND; Kautto EA; Passen EN; Stets C; Toland AE; Millis SZ; Meyer CF; Hays JL; Chen JL
    Oncologist; 2019 Jul; 24(7):973-979. PubMed ID: 30541756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combination of histone deacetylase and p53 expressions and histological subtype has prognostic implication in uterine leiomyosarcoma.
    Baek MH; Park JY; Park Y; Kim KR; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    Jpn J Clin Oncol; 2019 Aug; 49(8):719-726. PubMed ID: 31329907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
    Singh T; Prasad R; Katiyar SK
    Epigenetics; 2013 Jan; 8(1):54-65. PubMed ID: 23221619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting class I histone deacetylases in cancer therapy.
    Delcuve GP; Khan DH; Davie JR
    Expert Opin Ther Targets; 2013 Jan; 17(1):29-41. PubMed ID: 23062071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel therapeutic strategies targeting UCP2 in uterine leiomyosarcoma.
    Nagao Y; Yokoi A; Yoshida K; Sugiyama M; Watanabe E; Nakamura K; Kitagawa M; Asano-Inami E; Koya Y; Yoshihara M; Tamauchi S; Shimizu Y; Ikeda Y; Yoshikawa N; Kato T; Yamamoto Y; Kajiyama H
    Pharmacol Res; 2023 Mar; 189():106693. PubMed ID: 36773710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
    Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
    Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of HDACs in normal and malignant hematopoiesis.
    Wang P; Wang Z; Liu J
    Mol Cancer; 2020 Jan; 19(1):5. PubMed ID: 31910827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization.
    Levy B; Mukherjee T; Hirschhorn K
    Cancer Genet Cytogenet; 2000 Aug; 121(1):1-8. PubMed ID: 10958933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
    Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
    PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.